Ethical aspects of neonatal screening for sickle cell disease in Western European countries

Acta Paediatrica, International Journal of Paediatrics

Volumn 94, Issue 5, 2005, Pages 528-530

  De Montalembert, Mariane ^a   Bonnet, Doris ^b   Lena Russo, Danielle ^c   Briard, Marie Louise ^d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Inst de Recherche sur les Vaccins   (France)

^c CERGM   (France)

^d French Assoc for the Prevention and Screening of Children's Disabilities   (France)

Author keywords

Ethics; Neonatal screening; Sickle cell disease

Indexed keywords

BELGIUM; CULTURAL FACTOR; FRANCE; HETEROZYGOSITY; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; NEWBORN SCREENING; PARENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RELIGION; REVIEW; SICKLE CELL ANEMIA; UNITED KINGDOM; WESTERN EUROPE;

ANEMIA, SICKLE CELL; EMIGRATION AND IMMIGRATION; EUROPE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PARENTS;

EID: 18444370269     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250510026391     Document Type: Review

References (16)

1. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988;81:749-55.
2. Almeida AM, Henthorn JS, Davies SC. Neonatal screening for haemoglobinopathies: the results of a 10-year programme in an English Health Region. Br J Haematol 2001;112:32-5.
3. Gulbis B, Tshilolo L, Cotton F, Lin C, Vertongen F. Newborn screening for haemoglobinopathie: the Brussels experience. J Med Screen 1999;6:11-5.
4. Lena-Russo D, Bardakdjian J. Dépistage néonatal. In: Girot R, Bégué P, Galactéros F, editors. La drépanocytose. Paris: John Libbey Eurotext; 2003.
5. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. Br Med J 1995;311:1600-2.
6. Bardakdjian-Michau J, Guilloud-Batailie M, Maier-Redelsperger M, Elion J, Girot R, Feingold J, et al. Decreased morbidity in homozygous sickle cell disease detected at birth. Hemoglobin 2002;26:211-7.
7. Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. Health Technol Assess 1999;3:1-186.
8. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassemia: a systematic review with supplementary research. Health Technol Assess 2000;4:1-99.
9. Andrews LB. Newborn screening for sickle cell disease and other emoglobinopathies. Overview of legal issues. Pediatrics 1989;83:886-90.
10. Briard ML. Le défi éthique. Arch Pédiatr 2002;9 Suppl 2:157-8.
11. Rowley PT. Genetic screening: marvel or menace? Science 1984;225:138-44.
12. Billings PR, Kohn MA, de Cuevas M, Beckwith J, Alper JS, Natowicz MR. Discrimination of a consequence of genetic testing. Am J Hum Genet 1992;50:476-82.
13. Laird L, Dezateux C, Anionwu EN. Neonatal screening disorders: what about the carrier infants? Br Med J 1996;313:407-11.
14. Greengross P, Hickman M, Gill M, Dugan B, Davies SC. Outcomes of universal antenatal screening for haemoglobinopathies. J Med Screen 1999;6:3-10.
15. De Montalembert M, Guilloud-Bataille M, Ducros A, Galactéros F, Girot R, Hervé C, et al. Implications of prenatal diagnosis of sickle cell disease. Genet Couns 1996;7:9-15.
16. Bonnet D. Au delà du gène et de la culture. Hommes & Migrations 2000;1225:23-38.